Literature DB >> 6852909

Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant.

J A Cook, T W Holbrook.   

Abstract

The protective efficacy of glucan as an adjuvant with killed promastigotes of Leishmania donovani was compared with that of soluble or particulate fractions of the parasite. When these vaccine preparations were injected either intravenously or subcutaneously in CF-1 mice, glucan potentiated resistance against L. donovani infections as reflected by significant reductions in hepatic amastigote counts relative to infected control mice. The leishmanial antigens alone afforded no protection. Serum direct agglutination titers to leishmanial antigens were highest in all groups given the vaccine intravenously, whereas the delayed-type hypersensitivity response to the antigen was positive only in groups immunized subcutaneously with glucan as an adjuvant. Some index of protection and immune response against visceral infection with the parasite was seen in groups vaccinated with glucan and soluble antigens. However, the protection afforded by glucan and particulate antigens of L. donovani more closely paralleled the resistance of mice treated with glucan and unfractionated killed promastigotes. Further antigenic analysis of particulate fractions of L. donovani may optimize effective immunization when used with appropriate adjuvants, e.g., glucan.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852909      PMCID: PMC348155          DOI: 10.1128/iai.40.3.1038-1043.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Leishmania enriettii: radiation effects and evaluation of radioattenuated organisms for vaccination.

Authors:  A Lemma; L Cole
Journal:  Exp Parasitol       Date:  1974-02       Impact factor: 2.011

2.  Immunogenicity of a ribosomal antigen of Leishmania enriettii.

Authors:  P M Preston; D C Dumonde
Journal:  Trans R Soc Trop Med Hyg       Date:  1971       Impact factor: 2.184

3.  Vaccination of the African white-tailed rat, Mystromys albacaudatus, with sonicated Leishmania braziliensis panamensis promastigotes.

Authors:  B E Beacham; R Romito; H D Kay
Journal:  Am J Trop Med Hyg       Date:  1982-03       Impact factor: 2.345

Review 4.  The present and future of vaccination for cutaneous leishmaniasis.

Authors:  C L Greenblatt
Journal:  Prog Clin Biol Res       Date:  1980

5.  Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes.

Authors:  T W Holbrook; J A Cook; B W Parker
Journal:  Am J Trop Med Hyg       Date:  1981-07       Impact factor: 2.345

6.  Characterization of strains of Leishmania donovani.

Authors:  L A Stauber
Journal:  Exp Parasitol       Date:  1966-02       Impact factor: 2.011

7.  Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium.

Authors:  W Johnson
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

8.  Identification and characterization of protein antigens of Leishmania tropica isolates.

Authors:  E Handman; G F Mitchell; J W Goding
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

9.  Immunogenicity of Ribosomal Preparations from Yeast Cells of Histoplasma capsulatum.

Authors:  C Feit; R P Tewari
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

10.  A field trial of a vaccine against American dermal leishmaniasis.

Authors:  W Mayrink; C A da Costa; P A Magalhães; M N Melo; M Dias; A O Lima; M S Michalick; P Williams
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

View more
  5 in total

1.  Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants.

Authors:  Eilleen S Tackaberry; Fiona A Prior; Karen Rowlandson; Monika Tocchi; Jelica Mehic; Suzanne Porter; Mike Walsh; Mark R Schleiss; Peter R Ganz; Ravinder K Sardana; Illimar Altosaar; Anil K Dudani
Journal:  Mol Biotechnol       Date:  2008-04-16       Impact factor: 2.695

2.  Glucan-immunostimulant, adjuvant, potential drug.

Authors:  Vaclav Vetvicka
Journal:  World J Clin Oncol       Date:  2011-02-10

Review 3.  Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials.

Authors:  Vaclav Vetvicka; Luca Vannucci; Petr Sima; Josef Richter
Journal:  Molecules       Date:  2019-03-30       Impact factor: 4.411

4.  A review of adjuvants for Leishmania vaccine candidates.

Authors:  Joshua M Mutiso; John C Macharia; Michael M Gicheru
Journal:  J Biomed Res       Date:  2010-01

5.  β-Glucan and Parasites.

Authors:  V Vetvicka; R Fernandez-Botran
Journal:  Helminthologia       Date:  2018-07-28       Impact factor: 1.184

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.